MM13604 - National Coverage Determination 110.23: Allogeneic Hematopoietic Stem Cell Transplantation
This revised Article comprises Subregulatory Guidance about coverage for:
• Hematopoietic stem cell transplantation (HSCT) using bone marrow, peripheral blood, or umbilical cord blood stem cell products for Medicare patients
• All other indications for stem cell transplantation not otherwise specified
MLN Matters (MM) Articles are based on information contained within Change Requests (CRs). In this case, this article is based on content within CR13604 that is posted on the CMS website at https://www.cms.gov/files/document/r12948cp.pdf and https://www.cms.gov/files/document/r12948ncd.pdf.
Issued by: Centers for Medicare & Medicaid Services (CMS)
Issue Date: August 21, 2024
DISCLAIMER: The contents of this database lack the force and effect of law, except as authorized by law (including Medicare Advantage Rate Announcements and Advance Notices) or as specifically incorporated into a contract. The Department may not cite, use, or rely on any guidance that is not posted on the guidance repository, except to establish historical facts.